key: cord-0993947-40wljppd authors: Gong, Changlin; Song, Xiaojing; Li, Xiaoxia; Lu, Lianfeng; Li, Taisheng title: Immunological Changes after COVID-19 Vaccination in an HIV-Positive Patient date: 2021-08-19 journal: Int J Infect Dis DOI: 10.1016/j.ijid.2021.08.039 sha: e012dce5ed26768a09d626ad393172b7c4486db2 doc_id: 993947 cord_uid: 40wljppd Vaccination is an essential measure to stop the COVID-19 pandemic. We report a case of viral activation and CD4+ T cell loss after receiving inactivated COVID-19 vaccines (Sinopharm) in a treatment-naïve HIV-positive patient. Vaccination probably should be given only to PLWH receiving ART. . Concerns on the safety of vaccination in people living with HIV (PLWH) remain unsettled nowadays. Although no unusual adverse effects were found after vaccination in PLWH, there are still not enough data to definitively prove whether or not infection with human immunodeficiency virus (HIV) raises the risk of adverse events after vaccination [1] . Nevertheless, more than a year into the pandemic of coronavirus disease 2019 (COVID- 19) , several vaccines from different platforms have been developed, though no effective vaccines for HIV had been employed, probably due to the different mechanisms of infection [2] . Vaccination for this newly emerged infection in PLWH becomes of vital significance because of the potentially worse outcome after infection than in the general population [3, 4] . However, up till now, no large-scale study has been completed on the safety profiles of COVID-19 vaccines specifically within the PLWH population. We report a case of a 41-year-old, HIV-positive, male patient, with no other underlying chronic disease, who experienced marked decline in CD4+ T cell count and increase in viral load after vaccination against COVID-19. He works as a medical professional and was tested positive for HIV for the first time in 2015, which was speculated to be contracted via sexual behavior with another male subject, and no history of intravenous drug abuse or blood transfusion was reported. Antiviral therapy (ART) was not initiated due to personal A decrease in CD4+ T cell count was also observed in COVID-19 patients, and it seemed reasonable to assume that some components in the vaccine might also have the same effect. However, if that was the case, there should also be an increased proportion of naïve CD4+ T cells, as observed in COVID-19 patients [6] , contrary to the decreased proportion in this patient. Therefore, activation of HIV infection might be a better explanation than immune reaction to the COVID-19 vaccine alone. Although many inactivated vaccines were considered safe in PLWH, negative influences were reported, such as increased HIV viral load after influenza, pneumococcal, and tetanus vaccinations [7] [8] [9] . Despite subsequent controversy, our case raised the same concern. So, we propose that PLWH with unsatisfactory disease control are susceptible to vaccine-related HIV activation and CD4+ T cell loss, which might not be specific to COVID-19 vaccines. Our hypothesis is that the activated HIV infection could result in accelerated destruction of CD4+ T cells directly. Moreover, inappropriate stimulation of the immune system by HIV further accelerates the turnover of CD4+ T cells, manifesting in this case as a lower percentage of naïve (CD45RA+) CD4+ T cells and a higher percentage of memory CD4+ T cells. The activation of CD4+ T cells by exogenous antigens might also contribute to the decreased percentage of naïve CD4+ T cells [9, 10] . These processes eventually lead to the loss of all subsets of CD4+ T cells, with naïve CD4+ T cells being the most severely affected. In practice, different vaccination strategies are employed in different countries. According to the current guidelines in China, ART and stable viral control before COVID-19 vaccination in PLWH are emphasized [11] , which is consistent with our concern in this patient. Considering that the vast majority of vaccines available in China are inactivated vaccines, with PLWH excluded from their clinical trials [12, 13] , further evidence is needed to form a thorough vaccination strategy to safely provide immunization to as many people as possible. For all PLWH, we suggest ART be initiated as soon as possible, not only to preserve immune function and avoid secondary HIV transmission, but also to avoid the complicated interaction between HIV infection and other health conditions or procedures, such as vaccination in this case. As per the Centers of Disease Control and Prevention of the United States, immunocompromised patients may receive the COVID-19 vaccines [14] . In North America and Europe, mRNA vaccines and adenovirus vector vaccines are widely used, both of which allow constant production of exogenous antigens, probably raising the same issue as in this case. Though PLWH were included in the clinical trials of these vaccines, either good viral control or ART use was required in the criteria for eligibility [15, 16, 17] . Thus, more data are required to address this problem. For subunit vaccines, another major type of COVID-19 vaccines in China still under phase III clinical trial, PLWH were not involved in earlier studies [18] . However, worsening of HIV infection after receiving other subunit vaccines, such as a varicella-zoster vaccine, was also reported [19] . Therefore, safety of all COVID-19 vaccines in ART-naïve PLWH require further investigation. Presented here is a single case report, and well-controlled studies are needed to determine if vaccination carries the risk of deterioration of HIV infection in patients with or without satisfactory disease control. In these studies, PLWH should also be further grouped according to their disease control, in order to make better adjustments to the current guidelines. In conclusion, exogenous antigens might cause viral activation and CD4+ T cell depletion in PLWH. Thus, inactivated COVID-19 vaccines and likely similar vaccines should not be administered in treatment-naïve PLWH, but should be administered in patients with satisfactory disease control. Furthermore, all PLWH should receive ART as soon as possible. Adverse events after vaccination among HIVpositive persons SARS-CoV-2 and HIV-1 -a tale of two vaccines HIV/AIDS in the Era of COVID-19: A Juxtaposition of Two Pandemics COVID-19 Outcomes Among Persons Living With or Without Diagnosed HIV Infection in New York State Acute Immune Thrombocytopenia (ITP) Following COVID-19 Vaccination in a Patient With Previously Stable ITP. Open Forum Infect Dis Sharing CD4+ T Cell Loss: When COVID-19 and HIV Collide on Immune System Human immunodeficiency virus-type 1 replication can be increased in peripheral blood of seropositive patients after influenza vaccination Pneumococcal vaccination of HIV-infected individuals: safety and efficacy Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1 Vaccination and HIV: a review of the literature Chinese Society of Infectious Diseases. Expert recommendation for novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination in patients with HIV infection Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Authorized in the United States Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: a phase 1/2a randomized, placebo-controlled study Virological and immunological changes after receiving COVID-19 vaccines. (A) Changes in CD4+ T Cell Count after Vaccination. (B) Changes in Viral Load after Vaccination We would like to extend our appreciation to all healthcare workers and technicians working for the care of HIV patients in Peking Union Medical College Hospital. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. The patient described in the study gave consent to publish the history and laboratory test results anonymously.